Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients.
Sevoflurane, a new inhalational anesthetic agent has been shown to produce degradation products upon interaction with CO2 absorbants. Quantification of these sevoflurane degradation products during low-flow or closed circuit anesthesia in patients has not been well evaluated. The production of sevoflurane degradation products was evaluated using a low-flow anesthetic technique in patients receiving sevoflurane anesthesia in excess of 3 h. Sevoflurane anesthesia was administered to 16 patients using a circle absorption system with O2 flow of 500 ml/min and average N2O flow of 273 ml/min. Preoperative and postoperative hepatic and renal function studies were performed. Gas samples were obtained from the inhalation and exhalation limbs of the anesthetic circuit for degradation product analysis and analyzed by gas chromatography/mass spectrometry for four degradation products. The first eight patients received sevoflurane anesthesia using soda lime, and the following eight patients received anesthesia using baralyme as the CO2 absorbant. CO2 absorbant temperatures were measured during anesthesia. Of the degradation products analyzed, only one compound [fluoromethyl-2, 2-difluoro-1-(trifluoromethyl) vinyl ether], designated compound A, was detectable. Concentrations of compound A increased during the first 4 h of anesthesia with soda lime and baralyme and declined between 4 and 5 h when baralyme was used. Mean maximum inhalation concentration of compound A using baralyme was 20.28 +/- 8.6 ppm (mean +/- SEM) compared to 8.16 +/- 2.67 ppm obtained with soda lime, a difference that did not reach statistical significance. A single patient achieved a maximal concentration of 60.78 ppm during low-flow anesthesia with baralyme. Exhalation concentrations of compound A were less than inhalation concentrations, suggesting patient uptake.(ABSTRACT TRUNCATED AT 250 WORDS)
Frink
E J
EJ
Department of Anesthesiology, University of Arizona Health Sciences Center, Tucson 85724.
Malan
T P
TP
Morgan
S E
SE
Brown
E A
EA
Malcomson
M
M
Brown
B R
BR
D000042:Absorption; D000764:Anesthesia, Closed-Circuit; D000777:Anesthetics / Q000737:chemistry*; D001464:Barium / Q000737:chemistry; D017609:Barium Compounds; D017610:Calcium Compounds; D002126:Calcium Hydroxide / Q000737:chemistry; D002245:Carbon Dioxide / Q000737:chemistry*; D004987:Ethers / Q000032:analysis* / Q000737:chemistry*; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000032:analysis*; D008738:Methyl Ethers; D010087:Oxides; D011188:Potassium / Q000737:chemistry; D017680:Potassium Compounds; D000077149:Sevoflurane; D012972:Sodium Hydroxide / Q000737:chemistry; D013514:Surgical Procedures, Operative
D000777:Anesthetics; D017609:Barium Compounds; D017610:Calcium Compounds; D004987:Ethers; D006845:Hydrocarbons, Fluorinated; D008738:Methyl Ethers; D010087:Oxides; D017680:Potassium Compounds; C078747:fluoromethyl 2-methoxy-2-fluoro-1-(trifluoromethyl)vinyl ether; D002245:Carbon Dioxide; D001464:Barium; D000077149:Sevoflurane; C068927:Baralyme; C004569:soda lime; D012972:Sodium Hydroxide; C078745:fluoromethyl 2-methoxy-2,2-difluoro-1-(trifluoromethyl)ethyl ether; C078742:fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether; D002126:Calcium Hydroxide; D011188:Potassium